Nivolumab vs Tamoxifen
Nivolumab vs Tamoxifen: Overview
This comparison examines the pharmacological differences between Nivolumab and Tamoxifen.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Tamoxifen: Selective estrogen receptor modulator (SERM).
Pharmacokinetics
Half-life: Nivolumab — 27 days; Tamoxifen — 5-7 days.
Chemical Properties
Molecular Formula: Tamoxifen — C26H29NO.
Molecular Weight: Tamoxifen — 371.5150 g/mol.
Type: Nivolumab — Antibody; Tamoxifen — Small molecule.